Dose-dependent tumor regression during sirolimus therapy in an advanced juvenile nasopharyngeal angiofibroma case

Pediatr Int. 2024 Jan-Dec;66(1):e15807. doi: 10.1111/ped.15807.

Authors

Shin Kasai¹, Koshi Akahane¹, Minori Tamai¹, Kumiko Goi¹, Hiroki Ishii², Daiju Sakurai², Takeshi Inukai¹

Affiliations

¹ Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
² Department of Otorhinolaryngology, Head and Neck Surgery, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.

No abstract available

Keywords: alternate therapy; juvenile nasopharyngeal angiofibroma; sirolimus; therapeutic drug monitoring; unresectable case.

Publication types

Case Reports

MeSH terms

Adolescent
Angiofibroma* / diagnosis
Angiofibroma* / drug therapy
Antibiotics, Antineoplastic / administration & dosage
Antibiotics, Antineoplastic / therapeutic use
Dose-Response Relationship, Drug*
Humans
Male
Nasopharyngeal Neoplasms* / diagnosis
Nasopharyngeal Neoplasms* / drug therapy
Sirolimus* / administration & dosage
Sirolimus* / therapeutic use

Substances

Sirolimus
Antibiotics, Antineoplastic